

Federal investigators probe drug agency's crackdown on whistleblowers
The U.S. Office of Special Counsel (OSC) announced Wednesday that it is broadening its investigation into the Food and Drug Administration's alleged retaliation against nine whistleblowers.
Six current and former FDA employees are suing the agency, saying higher-ups pried into their personal email accounts and retaliated against them after they shared concerns with Congress and the OSC that the agency was approving unsafe medical devices.
Sen. Chuck Grassley (R-Iowa) has been leading the call for answers on Capitol Hill. He said Wednesday that he and Rep. Darrell Issa (R-Calif.) personally asked the OSC to open an investigation.
The independent federal investigative and prosecutorial agency said in a release that it has "received new and troubling allegations of retaliatory surveillance of OSC communications and other acts of retaliation against the whistleblowers, including FDA attempts to initiate criminal prosecution of the whistleblowers. We are reviewing these additional allegations and information from Congress and will take appropriate action."
The alleged threats against the employees — at least one of whom has been fired — are illegal under the Whistleblower Protection Act, the OSC warned.
"Monitoring employee emails with OSC or Congress could dissuade employees from making important disclosures," special counsel Carolyn Lerner said in the press release. "Monitoring communications with OSC is unacceptable. We encourage other agencies to review their policies to ensure that they are not monitoring or otherwise impeding employee disclosures to OSC or Congress."
—This story was updated at 3:45 p.m.








